Micelles and vesicles for the delivery of glycopeptides
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsRobin L. Polt, Dillon Hanrahan, Lajos Z. Szabo, Michael L Heien, Chenxi Liu
Life of this patent
Estimating the term…
Abstract
Methods for quality control and optimizing the formation and characterization of micelles, vesicles or other aggregates are described herein. Pharmaceutically relevant peptides may be modified to form glycopeptide surfactants which form micelles or other aggregates with another surfactant. Glycopeptide and glycolipid surfactants can aggregate to form particles that enhance drug delivery. The glycopeptide surfactants may be drugs or prodrugs which are delivered via the micelles or other aggregated structures.
Claims19
A supramolecular assembly comprising:
- a. at least one glycopeptide;
- and
- b. at least one amphipathic molecule;
- wherein said supramolecular assembly is capable of delivering the at least one glycopeptide to a cell;
- and wherein the at least one glycopeptide is a glycosylated angiotensin, glycosylated VEGF peptide fragment, glycosylated oxytocin, glycosylated VIP agonist, or glycosylated PACAP agonist.
A method of optimizing formation of a glycoaggregate, the method comprising:
- a. forming the glycoaggregate from at least two co-surfactants, wherein the first co-surfactant comprises a glycopeptide and the second co-surfactant comprises at least one amphipathic molecule;
- and wherein the at least one glycopeptide is a glycosylated angiotensin, glycosylated VEGF peptide fragment, glycosylated oxytocin, glycosylated VIP agonist, or glycosylated PACAP agonist;
- b. characterizing the glycoaggregate using spectroscopy to determine a diffusion coefficient;
- and
- c. comparing the diffusion coefficient to an optimal range of diffusion coefficients for a specific application to determine a quality of the glycoaggregate.
A glycopeptide delivery system, comprising a glycoaggregate comprising:
- a. a first co-surfactant comprising a glycopeptide;
- and
- b. a second co-surfactant comprising at least one amphipathic molecule;
- wherein the first co-surfactant and the second co-surfactant aggregate to form said glycoaggregate, wherein the glycoaggregate has a diffusion coefficient determined using spectroscopy;
- and wherein the at least one glycopeptide is a glycosylated angiotensin, glycosylated VEGF peptide fragment, glycosylated oxytocin, glycosylated VIP agonist, or glycosylated PACAP agonist.
Dependencies are inferred from the claim text.